Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation

AB-423 is a member of the sulfamoylbenzamide (SBA) class of hepatitis B virus (HBV) capsid inhibitors in phase 1 clinical trials. In cell culture models, AB-423 showed potent inhibition of HBV replication (50% effective concentration [EC(50)] = 0.08 to 0.27 μM; EC(90) = 0.33 to 1.32 μM) with no sign...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Mani, Nagraj, Cole, Andrew G., Phelps, Janet R., Ardzinski, Andrzej, Cobarrubias, Kyle D., Cuconati, Andrea, Dorsey, Bruce D., Evangelista, Ellen, Fan, Kristi, Guo, Fang, Guo, Haitao, Guo, Ju-Tao, Harasym, Troy O., Kadhim, Salam, Kultgen, Steven G., Lee, Amy C. H., Li, Alice H. L., Long, Quanxin, Majeski, Sara A., Mao, Richeng, McClintock, Kevin D., Reid, Stephen P., Rijnbrand, Rene, Snead, Nicholas M., Micolochick Steuer, Holly M., Stever, Kim, Tang, Sunny, Wang, Xiaohe, Zhao, Qiong, Sofia, Michael J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2018
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5971612/
https://ncbi.nlm.nih.gov/pubmed/29555628
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00082-18
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados